Scientists at St. Jude Children's Research Hospital have created a database that provides updated predicted structures on a regular basis, ensuring scientists can work with the most current ...
Structure Therapeutics' stock has declined over 40% since last year, but its differentiated technology platform and promising drug pipeline still support a "Buy" rating. Structure's lead candidate, ...
Eli Lilly is casting a long shadow over the GLP-1 market. Structure Therapeutics linked its oral candidate to significant reductions in blood sugar and weight in a phase 2a trial on Monday, only for ...
Structure Therapeutics' GSBR-1290 showed a placebo-adjusted mean weight loss of 6.2% at 12 weeks, suggesting potential despite initial underwhelming results. Comparatively, Eli Lilly’s orforglipron ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results